PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
738.04%
R&D growth while AVXL reduces spending. John Neff would investigate strategic advantage.
40.95%
G&A growth while AVXL reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
-9.94%
Other expenses reduction while AVXL shows 133.33% growth. Joel Greenblatt would examine efficiency.
178.81%
Operating expenses growth while AVXL reduces costs. John Neff would investigate differences.
178.81%
Total costs growth while AVXL reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
-9.94%
D&A reduction while AVXL shows 107.71% growth. Joel Greenblatt would examine efficiency.
-184.06%
EBITDA decline while AVXL shows 98.84% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-178.81%
Operating income decline while AVXL shows 78.93% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-185.77%
Other expenses reduction while AVXL shows 143.96% growth. Joel Greenblatt would examine advantage.
-184.01%
Pre-tax income decline while AVXL shows 112.00% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-184.01%
Net income decline while AVXL shows 112.00% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-184.12%
EPS decline while AVXL shows 112.50% growth. Joel Greenblatt would examine position.
-184.12%
Diluted EPS decline while AVXL shows 114.81% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.